ID: ALA5277833

Max Phase: Preclinical

Molecular Formula: C31H31F3N8O3

Molecular Weight: 620.64

Associated Items:

Representations

Canonical SMILES:  CN1CCN(c2ccc(Nc3ncc4c(=O)n(-c5cccc(OC(F)(F)F)c5)n(-c5cccc(C(C)(C)O)n5)c4n3)cc2)CC1

Standard InChI:  InChI=1S/C31H31F3N8O3/c1-30(2,44)25-8-5-9-26(37-25)42-27-24(28(43)41(42)22-6-4-7-23(18-22)45-31(32,33)34)19-35-29(38-27)36-20-10-12-21(13-11-20)40-16-14-39(3)15-17-40/h4-13,18-19,44H,14-17H2,1-3H3,(H,35,36,38)

Standard InChI Key:  QLHZJXOMHSBCGL-UHFFFAOYSA-N

Associated Targets(Human)

Serine/threonine-protein kinase PLK1 28605 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serine/threonine-protein kinase WEE1 1772 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 620.64Molecular Weight (Monoisotopic): 620.2471AlogP: 4.59#Rotatable Bonds: 7
Polar Surface Area: 113.57Molecular Species: NEUTRALHBA: 11HBD: 2
#RO5 Violations: 2HBA (Lipinski): 11HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.56CX Basic pKa: 7.96CX LogP: 5.80CX LogD: 5.13
Aromatic Rings: 5Heavy Atoms: 45QED Weighted: 0.27Np Likeness Score: -1.28

References

1. Guler S, DiPoto MC, Crespo A, Caldwell R, Doerfel B, Grossmann N, Ho K, Huck B, Jones CC, Lan R, Musil D, Potnick J, Schilke H, Sherer B, Simon S, Sirrenberg C, Zhang Z, Liu-Bujalski L..  (2023)  Selective Wee1 Inhibitors Led to Antitumor Activity In Vitro and Correlated with Myelosuppression.,  14  (5): [PMID:37197456] [10.1021/acsmedchemlett.2c00481]

Source